Navigation Links
Accentia Biopharmaceuticals Announces Favorable Interim Blinded,Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial,for Chronic Sinusitis

rous autoimmune diseases with an initial indication targeting refractory relapsing-remitting Multiple Sclerosis. Revimmune is based on pulsed, ultra-high dosing of a well-known chemotherapeutic agent under a risk management program. Additionally, through an investment strategy, the Company has acquired the majority ownership interest in Biovest International, Inc. ("Biovest"), (BVTI.OB) and a royalty interest in Biovest's lead drug candidate, BiovaxID(TM) and any other biologic products developed by Biovest. Biovest is currently conducting a pivotal Phase 3 clinical trial for BiovaxID which is a patient-specific anti-cancer vaccine focusing on the treatment of follicular non-Hodgkin's lymphoma. BiovaxID has been granted Fast Track status by the FDA. In addition to these product candidates, the Company has a specialty pharmaceutical business which markets products focused on respiratory disease and an analytical consulting business that serves customers in the biopharmaceutical industry. For further information, visit the Company Web site at www.accentia.net.

Forward-Looking Statements

Statements in this release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, statements about Revimmune(TM) SinuNase(TM), BiovaxID(TM), AutovaxID(TM), CRSFungal Profile(TM) and any other statements relating to products, product candidates, product development programs the FDA or clinical study process including the commencement, process or completion of clinical trials or the regulatory process. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, expectations and intentions and other statements identified by words such as "may," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans" or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties, and oth
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Accentia Biopharmaceuticals Scientific Presentations Demonstrate Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at the Annual Meeting of the American Academy of Allergy, Asthma, and Immunology
2. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
3. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
4. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:8/3/2015)... , August 3, 2015 ... is expected to reach USD 24.7 billion by ... View Research Inc. Growing prevalence of neurological and ... equipments market over the forecast period. The presence ... and cryotherapy, advancement in the technologies coupled with ...
(Date:8/3/2015)... 3, 2015 Biosensors International Group, Ltd. ... BIOS.SI; SGX: B20), a developer, manufacturer and marketer ... for its first fiscal quarter ended 30 June ... and Recent Developments: , Biosensors ... cost structure, driven by lower operating expenses and ...
(Date:8/3/2015)... , Aug. 3, 2015  CytomX, a ... of cancer, today announced the promotion of several ... Debanjan Ray , who previously served as vice ... been promoted to senior vice president of corporate ... Ray held positions as the vice president of ...
Breaking Medicine Technology:Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 2Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 3Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 4Physiotherapy Equipments Market Worth $24.7 Billion By 2022: Grand View Research, Inc. 5Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 2Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 3Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 4Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 5Biosensors Reports Financial Results for the First Quarter of Fiscal Year 2016 6CytomX Announces Management Team Promotions 2CytomX Announces Management Team Promotions 3
... N.J., Jan. 19, 2011 Today, Novo Nordisk announced ... for the Eastern District of Michigan issued an adverse ... US Patent No. 6,677,358. The district court ruled that ... and metformin for the treatment of type 2 diabetes, ...
... Progressive Medical, Inc., a leading pharmacy benefit manager and ... no-faulty auto industries, has named Kevin Banion as chief ... as president of Progressive Medical. This strategic move for ... Bianconi recently announced that he will serve as chairman ...
Cached Medicine Technology:Kevin Banion Named CEO of Progressive Medical, Inc. 2
(Date:8/3/2015)... ... ... Bayer has agreed to pay $56.9 million to set up a settlement program ... suffered an arterial blood clot including stroke and heart attack. The litigation involving product ... ongoing for well-over five years. In 2009, lawsuits filed against Bayer involving Yaz, Yasmin ...
(Date:8/3/2015)... ... 03, 2015 , ... Pitt Researchers to Monitor Resistance to ... School of Medicine are leading a five-year, $5 million initiative to monitor drug ... A cooperative agreement awarded by the U.S. Agency for International Development (USAID), will ...
(Date:8/3/2015)... ... 03, 2015 , ... A recent survey by the ... Hispanics believe people can positively affect their diabetes, few look beyond diet changes ... diet changes was important. Far fewer participants mentioned the need for exercise (30%), ...
(Date:8/3/2015)... ... August 03, 2015 , ... Dental practice in Los Angeles , Sunset ... people know that general health emergencies, such as broken arms or a heart attack, ... where to turn to during a dental emergency. This is important, because dental trauma ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... The art ... experience. Learning from her grandmother’s side at a young age, Nasreen Zereshki was extremely ... has decided to share her cookbook Recipes from My Persian Kitchen with the world. ...
Breaking Medicine News(10 mins):Health News:Bayer Agrees To Settle Yaz Aterial Blood Clot Lawsuits 2Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 2Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 3Health News:$5M Effort to Guide Use of HIV Prevention Meds in Africa 4Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 2Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 4Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 2Health News:Los Angeles Dental Practice, Sunset Plaza Dental, Now Offers Emergency Dental Services 3Health News:Persian Cuisine: Colorful and Extremely Healthy 2
... University determined that immune responses to the tetanus vaccine ... (MTX) was compared with MTX alone in patients with ... (Pneumovax pneumonia vaccine), however, were reduced in RA patients ... published in the January 2010 issue of Arthritis ...
... SODA project has created a service-oriented ecosystem for ... software components in even low-cost devices in the ... of device to communicate using the same language ... will be in a wide range of applications ...
... and others interested in the chemical sciences are invited ... Chemical Society (ACS) Webinars, Your Career Matters! featuring speakers ... science and engineering professionals. Scheduled for Thursday, Jan. ... webinar will feature ACS President Joseph S. Francisco, Ph.D., ...
... ,A new study shows that poor lung function during ... including birth weight, height, and gender. Researchers from Newcastle University ... all aged 14 years. Follow-up data also were obtained for ... showed that several factors were related to poorer lung function ...
... Mayo Clinic research study published in the January issue of ... that St. John,s wort is not an effective treatment for ... treat IBS, to date, no study has examined the success ... IBS. "Our study investigated if herbal antidepressants such as ...
... of a neuronal protein, researchers halted the growth of ... findings are reported online in the Journal of ... Formerly known for its effects on neuronal growth, ... produced by cells in human blood vessels. By diminishing ...
Cached Medicine News:Health News:Immune responses to tetanus vaccine unchanged for RA patients on rituximab 2Health News:Service-oriented ecosystem enables low cost devices to form interactive 'web of objects' 2Health News:Service-oriented ecosystem enables low cost devices to form interactive 'web of objects' 3Health News:ACS Webinar features tips for using a chemistry degree in finding career opportunities 2Health News:News briefs from the January issue of Chest 2Health News:St. John's wort not helpful treatment for irritable bowel syndrome, Mayo Clinic researchers say 2
... and most versatile light source Luxtec offers. ... this unique light source allows to use ... instrument or two UltraLite Headlights at the ... white light that is as close to ...
Head-worn Loupe G3, Galilean teleloupe system....
... XL Advantage delivers higher magnification for advanced ... true image, even at the highest magnification. ... clarity and precise color rendition is ideal ... an anti-reflective coating produce a superior image. ...
... and high power negative lens delivering magnification ... benefit of this system is ease of ... made possible due to a superior depth ... and individual interpupillary adjustment provides stability for ...
Medicine Products: